🔴 Xenetic Biosciences is trading 5.94% down in pre-market over dilution concerns from proposed Santersus deal

Xenetic Biosciences is trading 5.94% down at $2.06 after its September 16, 2026 announcement of a proposed all-stock acquisition of Santersus AG.

• Existing shareholders retain approximately 15%; Santersus investors receive roughly 85%, raising dilution concerns.
• The combined business is expected to operate as Santersus Bio under a new ticker, subject to shareholder approval.
• A 48.71% selloff to $2.19 during September 16 session contrasted with higher U.S. index futures early September 17, indicating company-specific pressure, not market weakness.